Skip to main content
. 2020 Sep 15;11:653. doi: 10.3389/fendo.2020.00653

Table 4.

Comparison of the clinical outcome for the patients with high P4 levels on the day of hCG injection (n = 149) between P4 ratio ≤1.62 and >1.62 groups.

P4 ratio ≤1.62 >1.62 P-value
N (patients, cycles) 60 89
Age (years) 33.1 ± 3.6 33.1 ± 3.4 0.898
P4 level I (ng/ml) 1.82 ± 0.84 0.82 ± 0.43 <0.001
P4 level II (ng/ml, hCG day) 2.02 ± 0.88 2.87 ± 1.34 <0.001
LH (mIU/ml, hCG day) 2.3 ± 1.6 2.8 ± 2.1 0.165
E2 (pg/ml, hCG day) 2,441 ± 905 1,957 ± 1,017 0.004
Total FSH dosage 2,880 ± 565 2,804 ± 858 0.176
Oocyte number 11.0 ± 3.2 9.8 ± 3.6 0.051
MII no. 8.3 ± 3.2 7.7 ± 3.4 0.174
Total embryo no. 6.3 ± 2.8 6.0 ± 2.8 0.352
Day 3 good embryo rate 62.2 ± 25.0 65.3 ± 27.8 0.434
ET no. 3.1 ± 0.6 3.1 ± 0.7 0.645
Implantation rate 10.3 (19/184) 29.2 (81/277) <0.001
Pregnancy rate 20.0 (12/60) 59.6 (53/89) <0.001
Abortion rate 16.7 (2/12) 26.4 (14/53) 0.714
Live birth rate 15.0 (9/60) 43.8 (39/89) <0.001
Gestational age (weeks) 37.7 ± 1.5 36.7 ± 2.3 0.255
Birth weight (g) 2,821 ± 477 2,648 ± 687 0.452

Statistical methods: Mann-Whitney test, χ2 test and Fisher's exact test.

In the table, percentages are used to describe categorical data and mean ± SD used to describe a set of continuous data.

P4 level I, the progesterone levels on 2 days prior to hCG day; P4 level II, progesterone level on the day of hCG administration; FSH, follicle stimulating hormone; E2, estrogen; LH, luteinizing hormone; P4, progesterone; ET, embryo transfer; MII, oocyte with metaphase II.